What do systematic reviews say?

Health‐related quality of life · people with keloid scars

Scar severity validated by participants · people with keloid scars

Adverse events · people with keloid scars

Clinical improvement D60 or more ‐ not reported · people with mild/moderate/severe/critical COVID‐19

WHO progression score (level 7 or above) D28 ‐ not reported · people with mild/moderate/severe/critical COVID‐19

All‐cause mortality D60 or more · people with mild/moderate/severe/critical COVID‐19

Adverse events ‐ not reported · people with mild/moderate/severe/critical COVID‐19

Clinical improvement D60 or more ‐ not reported · people with mild/moderate/severe/critical COVID‐19

Adverse events ‐ not reported · people with mild/moderate/severe/critical COVID‐19

Clinical improvement D60 or more ‐ not reported · people with mild/moderate/severe/critical COVID‐19

WHO progression score (level 7 or above) D28 ‐ not reported · people with mild/moderate/severe/critical COVID‐19

All‐cause mortality · children and adults diagnosed with cystic fibrosis and chronic rhinosinusitis with nasal polyposis

4a.Death at any time during initial hospitalization – doxapram compared to no treatment for the treatment of apnea · treatment of apnea

4b. Death at any time during initial hospitalization – doxapram compared to alternative treatment for the treatment of apnea · treatment of apnea

5a. Moderate‐to‐severe neurodevelopmental disability or intellectual impairment after 2 years of age – doxapram compared to no treatment for the treatment of apnea · treatment of apnea

5b. Moderate‐to‐severe neurodevelopmental disability or intellectual impairment after 2 years of age – doxapram compared to alternative treatment for the treatment of apnea · treatment of apnea

5c. Moderate‐to‐severe neurodevelopmental disability or intellectual impairment after 2 years of age – doxapram as an adjunct to methylxanthine compared to methylxanthine alone for the treatment of apnea · treatment of apnea

side‐effects ‐ side‐effects causing abandon · treatment of apnea

1a.'Clinical apnea' after initiation of treatment – doxapram compared to no treatment for the prevention of reintubation · prevention of reintubation

2a. Failed apnea reduction after 2–7 days – doxapram compared to no treatment for the prevention of reintubation · prevention of reintubation